Safety and efficacy of high-dose ranimustine, cytarabine, etoposide and CY (MCVAC) regimen followed by autologous peripheral blood stem cell transplantation for high-risk diffuse large B-cell lymphoma

Jun Kato, Takehiko Mori, K. Yokoyama, Y. Tsukada, T. Ueda, Takayuki Shimizu, Shinichiro Okamoto

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The efficacy of high-dose chemotherapy followed by autologous hematopoietic SCT for relapsed diffuse large B-cell lymphoma (DLBCL) has been reported, but an optimal conditioning regimen has not been determined. This study was conducted to evaluate the safety and efficacy of the MCVAC regimen (consisting of ranimustine (MCNU), cytarabine, etoposide and CY) followed by autologous peripheral blood stem cell transplantation (PBSCT) for patients with high-risk or relapsed DLBCL. A total of 40 patients with DLBCL who received the MCVAC regimen followed by autologous PBSCT were retrospectively evaluated. Median follow-up duration of the surviving patients was 51.2 months (range, 5.4-151.2 months). At 5-year OS and PFS were 73.7% (95% confidence interval (CI), 58.6-88.8) and 62.5% (95% CI, 46.8-78.2), respectively. Although relapse remained the most frequent cause of treatment failure, late-onset adverse events were observed, including two cases of severe pulmonary impairment, and two cases of therapy-related myelodysplastic syndromes (MDS)/AML. In conclusion, the MCVAC regimen would be an effective and tolerable conditioning regimen without TBI for autologous PBSCT for high-risk or relapsed DLBCL. However, late-onset pulmonary toxicity and MDS/AML should be monitored.

Original languageEnglish
Pages (from-to)923-928
Number of pages6
JournalBone Marrow Transplantation
Volume46
Issue number7
DOIs
Publication statusPublished - 2011 Jul

Fingerprint

Peripheral Blood Stem Cell Transplantation
Lymphoma, Large B-Cell, Diffuse
Cytarabine
Etoposide
Safety
Myelodysplastic Syndromes
Confidence Intervals
Lung
Treatment Failure
Recurrence
Drug Therapy
ranimustine
Therapeutics

Keywords

  • autologous peripheral blood stem cell transplantation
  • diffuse large B-cell lymphoma
  • high-dose chemotherapy
  • MCVAC regimen
  • pulmonary toxicity

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

@article{11c493970862488380e69bdf220549ab,
title = "Safety and efficacy of high-dose ranimustine, cytarabine, etoposide and CY (MCVAC) regimen followed by autologous peripheral blood stem cell transplantation for high-risk diffuse large B-cell lymphoma",
abstract = "The efficacy of high-dose chemotherapy followed by autologous hematopoietic SCT for relapsed diffuse large B-cell lymphoma (DLBCL) has been reported, but an optimal conditioning regimen has not been determined. This study was conducted to evaluate the safety and efficacy of the MCVAC regimen (consisting of ranimustine (MCNU), cytarabine, etoposide and CY) followed by autologous peripheral blood stem cell transplantation (PBSCT) for patients with high-risk or relapsed DLBCL. A total of 40 patients with DLBCL who received the MCVAC regimen followed by autologous PBSCT were retrospectively evaluated. Median follow-up duration of the surviving patients was 51.2 months (range, 5.4-151.2 months). At 5-year OS and PFS were 73.7{\%} (95{\%} confidence interval (CI), 58.6-88.8) and 62.5{\%} (95{\%} CI, 46.8-78.2), respectively. Although relapse remained the most frequent cause of treatment failure, late-onset adverse events were observed, including two cases of severe pulmonary impairment, and two cases of therapy-related myelodysplastic syndromes (MDS)/AML. In conclusion, the MCVAC regimen would be an effective and tolerable conditioning regimen without TBI for autologous PBSCT for high-risk or relapsed DLBCL. However, late-onset pulmonary toxicity and MDS/AML should be monitored.",
keywords = "autologous peripheral blood stem cell transplantation, diffuse large B-cell lymphoma, high-dose chemotherapy, MCVAC regimen, pulmonary toxicity",
author = "Jun Kato and Takehiko Mori and K. Yokoyama and Y. Tsukada and T. Ueda and Takayuki Shimizu and Shinichiro Okamoto",
year = "2011",
month = "7",
doi = "10.1038/bmt.2010.243",
language = "English",
volume = "46",
pages = "923--928",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Safety and efficacy of high-dose ranimustine, cytarabine, etoposide and CY (MCVAC) regimen followed by autologous peripheral blood stem cell transplantation for high-risk diffuse large B-cell lymphoma

AU - Kato, Jun

AU - Mori, Takehiko

AU - Yokoyama, K.

AU - Tsukada, Y.

AU - Ueda, T.

AU - Shimizu, Takayuki

AU - Okamoto, Shinichiro

PY - 2011/7

Y1 - 2011/7

N2 - The efficacy of high-dose chemotherapy followed by autologous hematopoietic SCT for relapsed diffuse large B-cell lymphoma (DLBCL) has been reported, but an optimal conditioning regimen has not been determined. This study was conducted to evaluate the safety and efficacy of the MCVAC regimen (consisting of ranimustine (MCNU), cytarabine, etoposide and CY) followed by autologous peripheral blood stem cell transplantation (PBSCT) for patients with high-risk or relapsed DLBCL. A total of 40 patients with DLBCL who received the MCVAC regimen followed by autologous PBSCT were retrospectively evaluated. Median follow-up duration of the surviving patients was 51.2 months (range, 5.4-151.2 months). At 5-year OS and PFS were 73.7% (95% confidence interval (CI), 58.6-88.8) and 62.5% (95% CI, 46.8-78.2), respectively. Although relapse remained the most frequent cause of treatment failure, late-onset adverse events were observed, including two cases of severe pulmonary impairment, and two cases of therapy-related myelodysplastic syndromes (MDS)/AML. In conclusion, the MCVAC regimen would be an effective and tolerable conditioning regimen without TBI for autologous PBSCT for high-risk or relapsed DLBCL. However, late-onset pulmonary toxicity and MDS/AML should be monitored.

AB - The efficacy of high-dose chemotherapy followed by autologous hematopoietic SCT for relapsed diffuse large B-cell lymphoma (DLBCL) has been reported, but an optimal conditioning regimen has not been determined. This study was conducted to evaluate the safety and efficacy of the MCVAC regimen (consisting of ranimustine (MCNU), cytarabine, etoposide and CY) followed by autologous peripheral blood stem cell transplantation (PBSCT) for patients with high-risk or relapsed DLBCL. A total of 40 patients with DLBCL who received the MCVAC regimen followed by autologous PBSCT were retrospectively evaluated. Median follow-up duration of the surviving patients was 51.2 months (range, 5.4-151.2 months). At 5-year OS and PFS were 73.7% (95% confidence interval (CI), 58.6-88.8) and 62.5% (95% CI, 46.8-78.2), respectively. Although relapse remained the most frequent cause of treatment failure, late-onset adverse events were observed, including two cases of severe pulmonary impairment, and two cases of therapy-related myelodysplastic syndromes (MDS)/AML. In conclusion, the MCVAC regimen would be an effective and tolerable conditioning regimen without TBI for autologous PBSCT for high-risk or relapsed DLBCL. However, late-onset pulmonary toxicity and MDS/AML should be monitored.

KW - autologous peripheral blood stem cell transplantation

KW - diffuse large B-cell lymphoma

KW - high-dose chemotherapy

KW - MCVAC regimen

KW - pulmonary toxicity

UR - http://www.scopus.com/inward/record.url?scp=79960175327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960175327&partnerID=8YFLogxK

U2 - 10.1038/bmt.2010.243

DO - 10.1038/bmt.2010.243

M3 - Article

VL - 46

SP - 923

EP - 928

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 7

ER -